1 st half year results 2009 information meeting of 15 september 2009
1 / 34

1st half-year results 2009 - PowerPoint PPT Presentation

  • Updated On :

1 st half-year results 2009 Information meeting of 15 September 2009 . Contents. Business in the 1 st half of 2009 Prospects for the 2 nd half of 2009 Conclusion. Business in the 1 st half of 2009. Changing pharmacy market

Related searches for 1st half-year results 2009

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about '1st half-year results 2009' - Melvin

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
1 st half year results 2009 information meeting of 15 september 2009 l.jpg

1st half-year results 2009Information meeting of 15 September 2009

Contents l.jpg

Business in the 1st half of 2009

Prospects for the 2nd half of 2009


Business in the 1 st half of 2009 l.jpg

Business in the 1st half of 2009

Slide4 l.jpg

Changing pharmacy market

Continued actions by public authorities to control health expenditure

Rise of generics

Self-medication products on open access

May 2009: the European Court of Justice gave its verdict against opening up dispensing pharmacies’ capital

HPST (hospitals, patients, health, territories) law: positive effects for pharmacists

Even if, from a purely economic point of view, the 1st half-year did not lead to any real upturn for pharmacists, a certain number of decisions strengthened the profession and the pharmacist’s role in protecting public health.

In this context, pharmacists need effective support more than ever


Economic context

1st half of 2009

Slide5 l.jpg


Pharmacy Business France

  • More than 5,000 pharmacies equipped with LGPI/CIP-GS on 30/06 out of a total of 9,800 customers

  • 2.5 % rise in Turnover over the 1st half of 2009

    • Configuration sales stable (- 0.4 %)

    • Licences slightly down (-1.37 %)

    • Recurrent T/O up 6.95 %

  • Demonstrates once more the relevance of the Pharmagest Group’s business model.

Slide6 l.jpg

Pharmacy Business France


T/O boosted thanks to the satellite offer of high-margin products up 18.28 % compared with the 1st half of 2008.

  • For example:

  • To date, 1,300 pharmacies use one of the Group’s advertising tools at the point of sale (compared with 500 at the end of 2008), following Pharmagest’s acquisition of the Novax software and databases after that company’s compulsory liquidation:

    • 970 Offimédia contracts (contextual advertising tool developed by Pharmagest)

    • 330 Pharmaxess customers (tool developed by Novax for which Pharmagest now provides maintenance)

  • The PD (Pharmaceutical Dossier) is now in general use and has had a positive impact on our secure Internet access product Offisecure, up 33 % during the 1st half of 2009.

    • CNOP has just reported the 10,000th pharmacy to be connected to the PD

    • 62 % of the Pharmagest Group’s customers equipped with LGPI/CIP-GS have activated the PD

Slide7 l.jpg


Pharmacy Business BENELUX


  • 12.5 % share of the market in Belgium and 43 % in

  • Luxembourg

  • 678 customers, 2,300 stations installed

  • of which 143 customers equipped with the new Sabco Optimum and Ultimate solutions

  • T/O: 1.3 M€ (- 13 % compared with the 1st half of 2008)

  • in a context

    • of reorganising the managerial and sales structure

    • of putting the Pharmagest business model in place (30 months’ free maintenance)

Slide8 l.jpg


Laboratories Business

The Laboratories business grew 11.4 % in the 1st half of 2009

  • After a very difficult year for Laboratories in 2008 with direct repercussions on our product offer, the 1st half of 2009 shows that they have a new trust in the market.

    • 1st half-year growth of our:

      • information campaigns on the therapeutic environment,

      • contextual advertising

      • and online surveys

    • Our innovative Offidirect services (orders placed directly by the Pharmacist with the Laboratory without going through a distributor) as well as the Advertising Agency also continue to grow steadily.

Slide9 l.jpg


Laboratories Business


  • Pharmagest, in conjunction with Intermedix and IDS Santé, carried out a large national survey amongst 3 target groups: Pharmacists, Doctors, and Internet users

  • This barometer is an opportunity each year to measure changes in the needs of these 3 target groups and to understand the new problems they face.

  • The presentation of the results of this study to the different operators in the pharmaceutical industry on 3 July 2009 aroused great interest and made it possible to establish new, promising contacts.

Slide10 l.jpg

Pharmagest strengthens its presence in the high-growth EHPAD sector

After the strategic acquisition of MALTA Informatique, in April 2009 Pharmagest announced the acquisition of AZUR Software, a company which designs and publishes a range of management software for care homes for the elderly.

Acquisition method: purchase of Azur Software’s business financed with a bank loan.

The number of EHPAD customers thus increased to 750 (Malta + Azur) and the share of the sector market to 7 % (out of a total of 11,000 existing care homes).

The software range offered by Malta Informatique, and more especially the reference software for EHPADs, TITAN, is now strengthened by Azur Software’s software MdRWIN, MEDIC and EHPADIAG, the latter being the main software on the market for self-evaluation of the quality of these institutions.



Slide11 l.jpg

T/O for the 1 sectorst half of 2009 was 465 K€ (+ 56 %)

The number of new customers (44 during the 1st half-year) and of migrations of old Azur solutions to TITAN, clearly shows Malta’s commercial dynamism

Continued strengthening of quality product offer

The combining of the two teams as well as newly hired staff strengthen Malta’s geographic presence for customer service.

Malta Informatique

  • Extremely dynamic business with T/O growth of over 50 %

Slide12 l.jpg

In April 2009, Pharmagest set up VIP Pharma which acquired the “Gold Partner’s Card” business line from VISEOPHARMA.

Business: promoting loyalty programmes for dispensing pharmacists

Principle: VIP Pharma acts as an intermediary and provides the logistics between the pharmacist and its Laboratory partners.

The pharmacist proposes a sales promotion card to his customers

Sales of partner products earn points

In return for the points, the customer can receive free partner products.



Pharmagest invests in building loyalty of pharmacists’ customers

Financial results on 30 june 2009 l.jpg

Financial results the “Gold Partner’s Card” business line from VISEOPHARMA. on 30 June 2009

Slide14 l.jpg

Financial results on 30 June 2009 the “Gold Partner’s Card” business line from VISEOPHARMA.

Key figures

Slide15 l.jpg

Financial results on 30 June 2009 the “Gold Partner’s Card” business line from VISEOPHARMA.

Consolidated by business

  • The “configuration sales” business (hardware, network, licences) accounts for 60 % of the total turnover for HY1 2009 compared with 62 % in HY1 2008

  • The “maintenance, data bases” business accounts for 30.1 % of the total turnover for HY1 2009 compared with 29.4 % in HY1 2008

  • The “laboratories” business accounts for 3.54 % of the total turnover for HY1 2009 compared with 3.26 % in HY1 2008

  • New products account for 6.47 % of the total turnover for HY1 2009 compared with 5.6 % in HY1 2008, growth of 15.5 %

Slide16 l.jpg

Profit and loss account the “Gold Partner’s Card” business line from VISEOPHARMA.

Financial results on 30 June 2009

Slide17 l.jpg

Balance sheet the “Gold Partner’s Card” business line from VISEOPHARMA.

Financial results on 30 June 2009

* Item exceptionally high as a result of a large number of requests for financing from our customers being frozen by GE Capital, regularized in January 2009

Slide18 l.jpg

(*) Excluding securities available for sale 15.6 M€ the “Gold Partner’s Card” business line from VISEOPHARMA.

(**) Of which R&D – 0.8 M€

Financial results on 30 June 2009

Cash flow summary

Market capitalisation l.jpg
MARKET CAPITALISATION the “Gold Partner’s Card” business line from VISEOPHARMA.

On 30/06/2009, market capitalisation reached 114.4 M€.

On 03/09/2009, it was 120.75 M€

Share price trend since september 2008 on 4 september 2009 l.jpg
Share price trend the “Gold Partner’s Card” business line from VISEOPHARMA. since September 2008(on 4 September 2009)

Prospects l.jpg

PROSPECTS the “Gold Partner’s Card” business line from VISEOPHARMA.

Ehpad business l.jpg

EHPAD Business the “Gold Partner’s Card” business line from VISEOPHARMA.

Slide23 l.jpg

Full order books which lead us to expect explosive growth of the business

The TITAN software is seen more and more as an essential “core EHPAD business” solution offering a wide range of modules which reinforces its key position.

Continuous innovation policy put in place

Development of “global healthcare pricing”, integrating medicines into EHPADs’ budgets as well as the monitoring of medical and para-medical acts.


EHPAD Business

Pharmacy france l.jpg

PHARMACY FRANCE the business

Slide25 l.jpg

Prospects the business

Pharmacy France

A significant growth lever for turnover and gross margin

Slide26 l.jpg

Continued growth of turnover and profitability despite the difficult economic context

Thanks to improved productivity

And to continuing to build customer loyalty and expanding our service offer (training, local monitoring).

Increasing the rate of migrations from traditional solutions to LGPI/CIP-GS.

Mass promotion of our high-margin products and service offers

European development:

Serious study of external growth in progress


Pharmacy France

Pharmacy benelux l.jpg

PHARMACY BENELUX difficult economic context

Slide28 l.jpg

Commercial business difficult economic context

Search for agreements with pharmacy chains based on LGPI and Officentral

LGPI as well as our satellite offers available since June in multilingual versions making it possible to speed up deployment in Flanders (currently 6% share of the market)

Launch of our Offimedia product in Flanders and Luxembourg


Resources put in place to strengthen our presence in Flanders

Thanks to the ongoing reorganisation, we are aiming at our turnover for 2009 recovering to a figure equivalent to that in 2008.


Pharmacy BENELUX

Laboratories l.jpg

LABORATORIES difficult economic context

Slide30 l.jpg

Prospects difficult economic context


  • Commercial business

    • Favourable context since the start of 2009 with active canvassing and new partnerships

    • Acquisition of new customers and building loyalty of large accounts

    • Development of the Advertising Agency business

  • Development of the reputation of the Carevox.fr website (100,000 visitors/month) by advertising operations with a view to the site being included in advertising products dedicated to the pharmaceutical industry

Conclusion l.jpg

Conclusion difficult economic context

Slide32 l.jpg

A business model offering a dynamic of difficult economic contextsteady business growth

An excellent margin level

Promising new business sectors

An international development strategy which is becoming clearer


Slide33 l.jpg

Conclusion difficult economic context

Next Meetings

  • Investors’ meeting:

  • MID CAP EVENT PARIS 21 and 22September 2009

  • Financial publication:

  • Letter to shareholders October2009

  • Q3 2009 T/O press release 12 November 2009

Contacts l.jpg
Contacts difficult economic context

Managing Director


[email protected]

Shareholder and Investor Relations 


Tel.: 03 83 15 90 67 [email protected]

Press Relations


Isabelle APRILE

Tel.: 33 1 39 97 61 22 - [email protected]